Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | CCR9 | P51686 | 5/20 | 0.57 |
| ▸ | CCR2 | P41597 | 9/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 2/20 | 0.46 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.46 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL307594 | 0.82 | CYP2C9 (0.62) | TSHRCCR9CCR2CYP3A4 | |
| SCHEMBL344999 | 0.81 | CCR9 (0.62) | CCR9BDKRB1 | |
| SCHEMBL14304298 | 0.80 | CCR9 (0.41) | TSHRCCR9CCR2NAMPT | |
| SCHEMBL13146503 | 0.79 | PGAM1 (0.53) | TSHRCCR2PGAM1 | |
| SCHEMBL3083483 | 0.77 | CCR9 (0.65) | CCR9CCR2 | |
| SCHEMBL13146487 | 0.76 | LMNA (0.66) | CCR9CCR2PGAM1 | |
| SCHEMBL13146456 | 0.76 | CCR2 (0.62) | CCR2 | |
| SCHEMBL13146479 | 0.76 | CCR9 (0.84) | CCR9CCR2BDKRB1 | |
| SCHEMBL343166 | 0.76 | CCR9 (0.55) | CCR9NAMPTBDKRB1 | |
| SCHEMBL1104716 | 0.75 | CCR2 (0.54) | CCR2PGAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. | 2010-09-16 | — | — | US | disclosed |
| WO-2008008374-A2 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CCR2, CCR9, CCR1 | TSHR 1538/4885CCR9 2/4885CCR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.